Patient and disease characteristics
| Age, years | 54.1 (12.6) |
| Women, No. (%) | 272 (61.7) |
| Education≥12 years | 137 (31.3%) |
| Rheumatoid Arthritis, No. (%) | 156 (35.4) |
| Axial Spondyloarthritis, No. (%) | 120 (27.2) |
| Psoriatic Arthritis, No. (%) | 61 (13.8) |
| Other diagnoses, No. (%) | 104 (23.6) |
| Treatment, csDMARD, No. (%) | 121 (27.4) |
| Treatment, bDMARD, No. (%) | 280 (63.5) |
| Treatment, tsDMARD, No. (%) | 24 (5.4) |
| CRP, mg/L, n=440 | 0.4 (0.7) |
| Patient global, NRS 0–10 | 4.1 (2.5) |
| CDAI, n=194 | 11.1 (9.0) |
| CDAI≥22.1, n (%) | 20 (10.4) |
| BASDAI, n=118 | 3.8 (2.2) |
| BASDAI≥4, n (%) | 61 (51.7) |
| HAQ, n=317 | 1.1 (0.7) |
| BASFI, n=118 | 3.8 (2.3) |
| HADS-A, n=436 | 6.6 (4.0) |
| HADS-D, n=436 | 5.8 (4.3) |
Variables as mean (SD). Threshold of ≥22.1 indicates high disease activity.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biologic DMARD; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; HADS-A, Hospital Anxiety Depression Scale-Anxiety; HADS-D, Hospital Anxiety Depression Scale-Depression; HAQ, Health Assessment Questionnaire; NRS, Numerical Rating Scale; tsDMARD, targeted synthetic DMARD.